List view / Grid view
Medically active substances are usually distributed via the blood – either directly or indirectly. In many diseases, however, it is vital to transport the active substance as efficiently as possible to the required target site. This is the case for diseases of the central nervous system, so the treatment of…
In a preclinical study in mice and human cells, researchers report that selectively removing old or 'senescent' cells from joints could stop and even reverse the progression of osteoarthritis.
The gene MAFK is known to be induced by the TGF-β signalling pathway, which is involved in breast cancer development. Scientists reported that the MAFK protein, in turn, induced cancerous behaviours in cells by switching on the breast cancer-associated gene GPNMB. MAFK thus represents a link between TGF-β signalling and…
BenevolentAI, a British artificial intelligence company, has partnered with MRC Technology (MRCT), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
Draper's Joe Charest explains how synthetic organoids can lead to safer drug testing, and why organ-on-a-chip technology is the future of drug discovery...
The human body’s peripheral nervous system could be capable of interpreting its environment and modulating pain, neuroscientists have established, after successfully studying how rodents reacted to stimulation.
Plasticell, a developer of stem cell technologies and cell-based therapies, has signed agreements with the Agency for Science, Technology and Research (A*STAR) and the Nanyang Technological University (NTU) to progress its therapeutic stem cell pipeline.
A new study has found that stem cell therapy can reduce lung inflammation in an animal model of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Although, still at a pre-clinical stage, these findings have important potential implications for the future treatment of patients.
Lone Friis and David Matthews discuss developability assessment of therapeutic antibodies, and Negin Mokhtari and colleagues explain nanoparticle-mediated enzyme delivery for application in cancer therapy...
SMi Group have released a series of interviews ahead of the industry gathering on pain management, Pain Therapeutics 2017.
10 March 2017 | By Charles River
This webinar explores neurological ion channel therapeutic and liability targets, featuring four subtypes of NMDA receptors. We also discuss the rationale and options for assessment of therapeutic compounds on panels of CNS ion channels for evaluating their risk for CNS liabilities...
Developability assessment is a broad term covering the evaluation of potential therapeutic candidates’ drug-like properties, manufacturability and safety profile. It is important to carry out this assessment as early as possible in the pre-clinical stage development to select the candidate with the most stable profile. This can minimise the risks…
Cancer Research UK announced that four international teams are the first recipients of its global £100m Grand Challenge competition, which aims to overcome the biggest challenges facing cancer researchers in a global effort to beat cancer sooner.
Recent findings by Japanese scientists may be a breakthrough in developing a silver bullet for the treatment of septic shock.
The Oncolytic Virotherapy Europe Congress is the only conference in Europe dedicated specifically to the Oncolytic Virotherapy and converting research into the next generation of clinically-relevant virotherapeutics.
